| Literature DB >> 23437306 |
Dora Rolo1, Alexandra S Simões, Arnau Domenech, Asunción Fenoll, Josefina Liñares, Hermínia de Lencastre, Carmen Ardanuy, Raquel Sá-Leão.
Abstract
We aimed to obtain insights on the nature of a collection of isolates presumptively identified as atypical Streptococcus pneumoniae recovered from invasive and non-invasive infections in Spain. One-hundred and thirty-two isolates were characterized by: optochin susceptibility in ambient and CO(2)-enriched atmosphere; bile solubility; PCR-based assays targeting pneumococcal genes lytA, ply, pspA, cpsA, Spn9802, aliB-like ORF2, and a specific 16S rRNA region; multilocus sequence analysis; and antimicrobial susceptibility. By multilocus sequence analysis, 61 isolates were S. pseudopneumoniae, 34 were pneumococci, 13 were S. mitis, and 24 remained unclassified as non-pneumococci. Among S. pseudopneumoniae isolates, 51 (83.6%) were collected from respiratory tract samples; eight isolates were obtained from sterile sources. High frequency of non-susceptibility to penicillin (60.7%) and erythromycin (42.6%) was found. Only 50.8% of the S. pseudopneumoniae isolates displayed the typical optochin phenotype originally described for this species. None harbored the cpsA gene or the pneumococcal typical lytA restriction fragment length polymorphism. The Spn9802 and the specific 16S rRNA regions were detected among the majority of the S. pseudopneumoniae isolates (n = 59 and n = 49, respectively). The ply and pspA genes were rarely found. A high genetic diversity was found and 59 profiles were identified. Among the S. pneumoniae, 23 were capsulated and 11 were non-typeable. Three non-typeable isolates, associated to international non-capsulated lineages, were recovered from invasive disease sources. In conclusion, half of the atypical pneumococcal clinical isolates were, in fact, S. pseudopneumoniae and one-fourth were other streptococci. We identified S. pseudopneumoniae and non-typeable pneumococci as cause of disease in Spain including invasive disease.Entities:
Mesh:
Year: 2013 PMID: 23437306 PMCID: PMC3578818 DOI: 10.1371/journal.pone.0057047
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Genetic relationships of the strains determined by MLSA.
The symbols indicate: grey triangle, non-invasive disease strains; black circle, invasive disease strains; white square, strains described in other studies. [15], [17], [35], [36], [37].
Phenotypic and genotypic characterization of MLSA typeable isolates.
| MLSA classification (%) | ||||
|
|
|
| ||
| typeable (n = 23) | nontypeable (n = 11) | |||
|
| ||||
| optochin susceptibility (≥14 mm) | ||||
| 5% CO2 | 10 (16.4) | 8 (34.8) | 6 (54.6) | 4 (30.8) |
| ambient atmosphere | 39 | 21 (91.3) | 6 | 8 |
| bile solubility | 22 (36.1) | 22 (95.7) | 11 (100) | 2 (15.4) |
|
| ||||
| PCR-based | ||||
| pneumococcal | 0 (0) | 23 (100) | 11 (100) | 0 (0) |
| pneumococcal specific 16S-rRNA | 49 (80.3) | 23 (100) | 11 (100) | 2 (15.4) |
|
| 59 (96.7) | 23 (100) | 8 (72.7) | 8 (61.5) |
|
| 1 (1.6) | 21 (91.3) | 10 (90.9) | 7 (53.8) |
|
| 0 (0.0) | 17 (73.9) | 2 (18.2) | 0 (0) |
|
| 61 (100.0) | 7 (30.4) | 9 (81.8) | 12 (92.3) |
| RFLP signatures | ||||
| pneumococcal | 0 (0)/61 (100) | 23 (100) | 9 (81.8)/2 (18.2) | 0/11(84.6) |
|
| 7 (11.5)/54 (88.5) | 23 (100)/0 (0) | 11 (100)/0 | 2 (15.4)/7 (53.8) |
11 strains did not grow in an ambient atmosphere, among the 39 isolates susceptible to optochin in ambient atmosphere, 31 were resistant in CO2.
3 strains did not grow in ambient atmosphere.
2 strains did not grow in ambient atmosphere.
2 strains were not screened.
2 strains did not amplify, 2 yielded a mixed pattern.
Antimicrobial susceptibility of 61 S. pseudopneumoniae clinical isolates.
| Antibiotic | MIC (mg/L) | No. non-susceptible isolates (%) | ||
| Range | MIC50 | MIC90 | ||
| Penicillin | ≤0.03–2 | ≤0.03 | 0.5 | 37 (60.7%) |
| Cefotaxime | ≤0.03–1 | ≤0.12 | 0.25 | 2 (3.3%) |
| Erythromycin | ≤0.12–≥128 | ≤0.12 | ≥32 | 26 (42.6%) |
| Clindamycin | ≤0.12–≥128 | ≤0.12 | ≥0.5 | 13 (21.3%) |
| Cotrimoxazole | ≤0.5/9.5–≥2/38 | ≤0.5/9.5 | ≥2/38 | 24 (39.3%) |
| Tetracycline | ≤0.12–64 | ≤0.25 | 4 | 18 (29.5%) |
| Ciprofloxacin | ≤0.12–32 | ≤1 | ≤1 | 6 (9.8%) |
| Levofloxacin | ≤0.12–≥16 | ≤1 | ≤1 | 3 (4.9%) |
| Chloramphenicol | ≤2–4 | ≤2 | ≤2 | 0 (0%) |
Figure 2Representation of the S. pseudopneumoniae population by eBURST analysis.
Each point represents a different allele combination. Solid lines, single-locus variants; dashed circles, invasive disease isolates; larger circles indicate two isolates with the same allele combination.
Properties of S. pneumoniae clinical isolates.
| Serotypes | Sequence type | MLST allelic profile | Antimicrobial non-susceptibility pattern | Observations |
| 6B | 90 (1) | 5-6-1-2-6-3-4 | PEN, TET, ERY, CLI, CTX | Spain6B-ST90 |
| 94 (1) | 5-6-1-2-6-3-54 | PEN, TET, CHL, ERY, CLI, SXT, CIP | Spain6B-ST90 SLV | |
|
| 32-28-1-1-15-52-15 | TET, ERY, CLI | ||
| 38 | 393 (2) | 10-43-41-18-13-49-6 | Susceptible | |
|
| 10-61-41-18-13-49-6 | Susceptible | ||
| 13 | 70 (1) | 2-13-1-4-6-12-1 | Susceptible | |
|
| 7-13- | Susceptible | ||
| 19F | 89 (1) | 5-5-7-7-8-5-1 | PEN, TET, CHL, SXT | |
|
| 5-5-7-7-8-5- | PEN, TET, CHL, ERY, CLI, CTX, SXT | ||
| 25A | 393 (1) | 10-43-41-18-13-49-6 | Susceptible | |
|
| 10-43-41-18-13-37-6 | PEN, SXT | ||
| 3 | 180 (1) | 7-15-2-10-6-1-22 | Susceptible | Netherlands3-ST180 |
| 4 | 247 (1) | 16-13-4-5-6-10-14 | Susceptible | |
| 7F | 2178 (1) | 10-20-14-1-6-20-29 | TET | Denmark12F-ST218 SLV |
| 10A |
| 5-13-4-4-6-1-20 | Susceptible | |
| 17A |
| 5- | Susceptible | |
| 18C | 191 (1) | 8-9-2-1-6-1-17 | Susceptible | Netherlands7F-ST191 |
| 19A | 81 (1) | 4-4-2-4-4-1-1 | PEN, TET, CHL, ERY, CLI, CTX, SXT, CIP, LEV | Spain23F-ST81 |
| 20 |
| 15- | Susceptible | |
| 22F | 2104 (1) | 2-16-1-4-6-1-1 | Susceptible | |
| 33F | 1012 (1) | 2-5-29-18-42-3-18 | TET, ERY, CLI | |
| 35A | 1273 (1) | 10-12-4-12-9-28-18 | Susceptible | |
| NT | 448 (2) | 8-5-2-27-2-11-71 | Susceptible | USANT-ST448 |
| 508 (2) | 13-8-65-1-60-16-6 | Susceptible | ||
| 66 (1) | 2-8-2-4-6-1-1 | PEN, TET, SXT, CIP, LEV | ||
| 72 (1) | 2-13-2-4-9-4-1 | Susceptible | ||
| 344 (1) | 8-37-9-29-2-12-53 | PEN, TET, ERY, SXT | NorwayNT-ST344 | |
| 942 (1) | 8-10-15-27-2-28-4 | PEN, SXT | ||
|
| 8-10-84-1-2-14-4 | Susceptible | ||
|
| 8-37-2-27-2-11-53 | Susceptible | USANT-ST448 DLV | |
|
| 8-178-9-29-2-12-15 | PEN, TET, ERY, CLI, SXT | NorwayNT-ST344 DLV |
Novel STs and alleles found in this study are represented in bold.
PEN, penicillin; CTX, cefotaxime; ERY, erythromycin; CLI, clindamycin; TET, tetracycline; CHL, chloramphenicol, SXT, trimethoprim-sulfamethoxazole non-susceptible; CIP, ciprofloxacin; LEV, levofloxacin.
International clones of PMEN; SLV, Single Locus Variant; DLV, Double Locus Variant.